US Market Report for Mechanical Thrombectomy Devices 2017 - MedCore

  • ID: 3960390
  • Report
  • Region: United States
  • 75 pages
  • iData Research
1 of 5

FEATURED COMPANIES

  • Boston Scientific
  • Codman & Shurtleff
  • Cyberonics
  • InoMed
  • Integra LifeSciences
  • Medtronic
  • MORE
There will be significant market growth in the mechanical thrombectomy market over the forecast period, driven by growth in unit sales as mechanical thrombectomy is adopted as standard of care for acute ischemic stroke patients. This market includes stent retrievers and suction thrombectomy catheters. The majority of the time a combination of the two categories is used but there a number of factors that can impact treatment decisions, one key factor being physician preference. Studies found new stent retriever devices are superior to first generation aspiration devices but there have been fewer studies comparing the second generation of both categories.

Prior to 2012 it was mainly aspiration used and then with the entrance of stent retrievers, they became the primary treatment. In the last year or so, combination therapy has become the most common. Both categories of devices have a role as certain devices appear to more successful based on the anatomy, clot morphology and clot locations. Additional clinical trials will influence whether the devices continue to be used in conjunction or whether one category will cannibalize shares form the other.
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Boston Scientific
  • Codman & Shurtleff
  • Cyberonics
  • InoMed
  • Integra LifeSciences
  • Medtronic
  • MORE
Table Of Contents I
List Of Figures Ix
List Of Charts Xi
Executive Summary
U.S. Neuromodulation, Neurovascular, Neurosurgical And Monitoring Device Market Overview
Competitive Analysis
Market Trends
Market Developments
Procedure Numbers
Procedure Codes Investigated
Markets Included
Key Report Updates
Version History
Research Methodology
1.1 Research Scope
1.2 9-Step Methodology
Step 1: Project Initiation & Team Selection
Step 2: Prepare Data Systems And Perform Secondary Research
Step 3: Preparation For Interviews & Questionnaire Design
Step 4: Performing Primary Research
Step 5: Research Analysis: Establishing Baseline Estimates
Step 6: Market Forecast And Analysis
Step 7: Identify Strategic Opportunities
Step 8: Final Review And Market Release
Step 9: Customer Feedback And Market Monitoring
Disease Overview
2.1 Basic Anatomy
2.2 Disease Pathology And Disorders
2.2.1 Introduction
2.2.2 General Diagnostics And Neurosurgery
2.2.3 Tumor And Brain Cancer
2.2.4 Brain Arteriovenous Malformations
2.2.5 Ischemic Stroke
2.2.6 Brain Aneurysm
2.2.7 Disorders Related To Cerebrospinal Fluids And Intracranial Pressure
2.2.7.1 Hydrocephalus And Intracranial Pressure Disorder
2.2.7.2 Cerebral Edema
2.2.8 Indication For Neuromodulation
2.2.9 Traumatic Brain Injury
Product Assessment
3.1 Product Portfolios
3.1.1 Mechanical Thrombectomy
3.1.1.1 Introduction
3.1.1.2 Product Matrix For Mechanical Trombectomy Device: Core Companies
3.2 Regulatory Issues And Recalls
3.2.1 Mechanical Thrombectomy
3.3 Clinical Trials
3.3.1 Mechanical Thrombectomy
Mechanical Thrombectomy Market
4.1 Introduction
4.2 Market Overview
4.3 Market Analysis And Forecast
4.3.1 Stent Retrievers
4.3.2 Thrombectomy Catheters
4.4 Drivers And Limiters
4.4.1 Market Drivers
4.4.2 Market Limiters
4.5 Competitive Market Share Analysis
Abbreviations
Appendix: Company Press Releases
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • Boston Scientific
  • Codman & Shurtleff
  • Cyberonics
  • InoMed
  • Integra LifeSciences
  • Medtronic
  • MORE
Ischemic Stroke is caused by an obstruction within a blood vessel that is supplying blood to the brain. This is often caused by blood clots but can also be caused by other substances like plaque. The gold standard treatment for strokes for many years has been the administration of clot dissolving or clot busting medication called tissue plasminogen activator (tPA). This type of drug must be administered as soon as possible, with a four hour window from symptom onset, to increase chances of recovery. A significant number of patients do not get to healthcare facilities quickly enough to meet that window and even some of those who do, later experience hemorrhagic complications from the medication. It is very effective for smaller clots but often fails to break up larger clots. Some patients cannot receive tPA, in which cases physicians rely on antiplatelet or anticoagulant medicine to ensure blood clots do not get larger.
Note: Product cover images may vary from those shown
5 of 5
Medtronic
Boston Scientific
St. Jude Medical
Cyberonics
Codman & Shurtleff
Stryker
Integra LifeSciences
InoMed
Mizuho America
RauMedic
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll